Bracket forms new SAB subcommittee

New entity focused on Alzheimer’s disease holds inaugural meeting at CTAD 2016

DDNews Staff
Register for free to listen to this article
Listen with Speechify
WAYNE, Pa.—Bracket, a clinical trial technology and specialty services provider with expertise in Alzheimer’s disease (AD), announced recently that its scientific advisory board (SAB) had formed an AD subcommittee—with the SAB deciding to hold that AD entity’s inaugural meeting at the Ninth Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference in December of last year in San Diego.
The subcommittee, chaired by and established in collaboration with Dr. Jeffrey Cummings, director of Cleveland Clinic’s Lou Ruvo Center for Brain Health and Camille, and Larry Ruvo, chair of the Neurological Institute of Cleveland Clinic, will focus exclusively on maintaining Bracket’s awareness and involvement in AD research advancement, field changes, emerging technologies and competitive landscape.
As a specialty services provider with specific expertise in AD trial technology, including the development and launch of Bracket eCOA, Bracket’s subcommittee will build upon the company’s strategic agenda to capture data using technology, finding innovative ways to minimize error-prone human factors in clinical trials. The committee will be critical in assessing the acceptability of new technologies to sites.
“Bracket’s SAB is well-represented across various therapeutic areas, but we maintain a specialized focus on AD in effort to combat the many challenges facing its clinical trials today,” said Jeff Kinell, CEO of Bracket. “We’ve invested tremendously on improving outcomes in the area and we’re hopeful that this focused subcommittee will connect the right data, minds and initiatives to move AD trials forward.”
With plans to meet several times per year at relevant meetings such as the American Academy of Neurology Annual Meeting and Alzheimer’s Association International Conference, the committee will share meeting notes and coordinate on common projects with Bracket’s SAB, while operating independently.
Also in early 2017 news from the company, Bracket announced the addition of Jennifer Peters to its growing team as the company’s new senior vice president and general manager for the Scientific Services division. In this role, she will be responsible for Bracket’s work in rater training, quality assurance and electronic clinical outcomes assessments. Peters joins Bracket with a strong skill set and demonstrated record building technology-based businesses in life sciences.
She has more than 14 years of life-sciences industry experience, most recently serving as a founder and chief experience officer of Greenphire, a global provider of disruptive clinical trials payment and process optimization technology products serving pharmaceutical sponsors, biotech companies and CROs. She led Greenphire from an idea-stage startup, with three founding employees at its inception in October 2007, to a global technology enterprise with more than 100 employees and over 500 clients when it was sold to a private equity firm in 2014.

DDNews Staff

Published In:

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue